SLC5A2 and urothelial carcinoma: Retrospective studies on diabetic bladder cancer patients treated with SGLT-2 inhibitors [58] can answer whether the high risk of urothelial carcinoma in diabetic patients stems from hyperglycemia or glucosuria.